Epigenomics Q1 Revenues Rise 15 Percent as it Awaits FDA, CFDA Decisions | GenomeWeb

NEW YORK (GenomeWeb) – Epigenomics today reported a 15 percent year-over-year increase in its first quarter revenues as product revenues were up 32 percent.

The German-American molecular diagnostics company said that for the three months ended March 31, revenues rose to €407,000 ($559,000) from €355,000. Product revenues increased to €215,000 from €163,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.